Description

Zolendrovista (Zoledronic Acid) Concentrated Solution for Infusions 4 mg/5 ml. 5 ml Vial №1

Ingredients:

• Each 5 ml vial contains 4 mg of zoledronic acid.

Dosage:

• The recommended dosage of Zolendrovista is determined by a healthcare professional based on the patient’s condition. It is typically administered as an intravenous infusion over a specific period.

Indications:

• Zolendrovista is indicated for the treatment of osteoporosis in postmenopausal women and for the prevention of skeletal-related events in patients with bone metastases.

Contraindications:

• Do not use Zolendrovista if you have a known hypersensitivity to zoledronic acid or any of the ingredients in the solution. It is also contraindicated in patients with severe renal impairment.

Directions:

• Zolendrovista should only be administered by healthcare professionals experienced in intravenous therapy. The infusion rate should be carefully monitored to prevent adverse reactions.

Scientific Evidence:

• Zoledronic acid, the active ingredient in Zolendrovista, is a bisphosphonate that inhibits bone resorption. Studies have shown its effectiveness in reducing fractures in postmenopausal women with osteoporosis and preventing skeletal-related events in cancer patients with bone metastases.

Additional Information:

• Zolendrovista has demonstrated efficacy in improving bone mineral density and reducing fractures in clinical trials. Common side effects include flu-like symptoms and transient increases in serum creatinine levels.

Zoledronic acid inhibits farnesyl pyrophosphate synthase, reducing osteoclast activity and bone resorption. Compared to other bisphosphonates, Zolendrovista offers similar efficacy in osteoporosis and bone metastases treatment with the convenience of a once-yearly infusion regimen.